Ball & CO Wealth Management Inc. Viking Therapeutics, Inc. Transaction History
Ball & CO Wealth Management Inc.
- $93.3 Million
- Q1 2025
A detailed history of Ball & CO Wealth Management Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Ball & CO Wealth Management Inc. holds 100 shares of VKTX stock, worth $2,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$2,862
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
439Shares Held
64.7MCall Options Held
5.79MPut Options Held
3.72M-
Vanguard Group Inc Valley Forge, PA10.2MShares$291 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$172 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$141 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.2 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.7 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.19B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...